Tr 1 X announced FDA approval for the IND of its cell drug TRX103, an engineered Tr1 Treg cell therapy for refractory Crohn's disease. Tr 1 X plans to start phase 1 / 2a clinical trials and be the first patient by the end of 2024.

Earlier this year, Tr 1 X announced the completion of A $75 million Series A funding round to focus on the development of new allogeneic regulatory T-cell (Treg) and CAR-Treg cell therapies to target and potentially cure autoimmune and inflammatory diseases.

The company's scientific research is mainly based on the research results of Maria Grazia Roncarolo, M. D., the scientific founder of Tr 1 X, who is the discoverer of type 1 regulatory T cells (Tr 1). Tr 1 cells are a differentiated subset of regulatory T cells that are essential for maintaining balance and tolerance in healthy humans and have multiple important functions. These functions include inhibition of local inflammation and downregulation of the inflammasome, inhibition of pathogenic effector T cell responses, and induction of long-term tolerance, which has been observed in preclinical models and in patients.

The proprietary technology for Tr 1 X transforms CD4 + T cells isolated from healthy donors into Treg-like cells with functions and features similar to native Tr 1 cells. These cells are further engineered to target specific tissues or organs to achieve locally targeted immunomodulation. With a proprietary GMP-level closed-loop system, the Tr 1 X can scale up products and provide consistency, quality, and reliability.

The company's product recommendation:

1.117391-49-8  https://www.bicbiotech.com/product_detail.php?id=5425

2.117391-51-2  https://www.bicbiotech.com/product_detail.php?id=5426

3.412925-58-7  https://www.bicbiotech.com/product_detail.php?id=5427

4.5678-46-6  https://www.bicbiotech.com/product_detail.php?id=5428

5.63974-15-2  https://www.bicbiotech.com/product_detail.php?id=5429